The role of procalcitonin outside of the Intensive Care Unit (ICU): A multidisciplinary approach

M. Fantoni, E. Taddei, R. Cauda, R. Antonelli Incalzi, A. Capone, F. Cortese, M. Sanguinetti, F. Spandonaro, A. Urbani, R. Murri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: Biochemical markers are commonly used in medicine to guide diagnostic investigation or therapy duration and/or monitor treatment efficacy. Due to the emergence and spread of antimicrobial resistance, markers able to prompt a more rational use of antimicrobial therapy are regarded with the greatest attention. Procalcitonin (PCT) certainly stands out among others, yet its role must be better established especially outside of the critical care area. Data about PCT utilization in non-critical patients, optimal negativity cut-offs as well as a protocol for measurement timing are all lacking. MATERIALS AND METHODS: To address these issues, a focus group was set up to propose and endorse shared statements regarding the most beneficial use of PCT in real life as infection marker for non-critical patients, based on the authors' experience and a review of recent literature. RESULTS: A group of nine experts in the fields of Infectious Diseases, Internal Medicine, Microbiology, Clinical Chemistry, Surgery and Medical Economics participated in the discussion of nine pre-specified statements. CONCLUSIONS: The potential role for PCT in differentiating infectious and non-infectious clinical syndromes and guiding antimicrobial therapy discontinuation was acknowledged. Moreover, a shared measurement protocol and desirable cut-offs for the non-critical area were proposed. Finally, observations were made about a reasonable selection of the patient population to be tested.

Original languageEnglish
Pages (from-to)2978-2985
Number of pages8
JournalEuropean Review for Medical and Pharmacological Sciences
Volume23
Issue number7
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Calcitonin
Intensive Care Units
Infectious Disease Medicine
Medical Economics
Clinical Chemistry
Critical Care
Internal Medicine
Microbiology
Focus Groups
Patient Selection
Therapeutics
Biomarkers
Medicine
Infection
Population

Keywords

  • Antibiotic therapy
  • Antimicrobial stewardship
  • Biomarkers
  • Procalcitonin
  • Sepsis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The role of procalcitonin outside of the Intensive Care Unit (ICU) : A multidisciplinary approach. / Fantoni, M.; Taddei, E.; Cauda, R.; Antonelli Incalzi, R.; Capone, A.; Cortese, F.; Sanguinetti, M.; Spandonaro, F.; Urbani, A.; Murri, R.

In: European Review for Medical and Pharmacological Sciences, Vol. 23, No. 7, 01.01.2019, p. 2978-2985.

Research output: Contribution to journalArticle

@article{a7a103fa14304c32baa65464d931e983,
title = "The role of procalcitonin outside of the Intensive Care Unit (ICU): A multidisciplinary approach",
abstract = "OBJECTIVE: Biochemical markers are commonly used in medicine to guide diagnostic investigation or therapy duration and/or monitor treatment efficacy. Due to the emergence and spread of antimicrobial resistance, markers able to prompt a more rational use of antimicrobial therapy are regarded with the greatest attention. Procalcitonin (PCT) certainly stands out among others, yet its role must be better established especially outside of the critical care area. Data about PCT utilization in non-critical patients, optimal negativity cut-offs as well as a protocol for measurement timing are all lacking. MATERIALS AND METHODS: To address these issues, a focus group was set up to propose and endorse shared statements regarding the most beneficial use of PCT in real life as infection marker for non-critical patients, based on the authors' experience and a review of recent literature. RESULTS: A group of nine experts in the fields of Infectious Diseases, Internal Medicine, Microbiology, Clinical Chemistry, Surgery and Medical Economics participated in the discussion of nine pre-specified statements. CONCLUSIONS: The potential role for PCT in differentiating infectious and non-infectious clinical syndromes and guiding antimicrobial therapy discontinuation was acknowledged. Moreover, a shared measurement protocol and desirable cut-offs for the non-critical area were proposed. Finally, observations were made about a reasonable selection of the patient population to be tested.",
keywords = "Antibiotic therapy, Antimicrobial stewardship, Biomarkers, Procalcitonin, Sepsis",
author = "M. Fantoni and E. Taddei and R. Cauda and {Antonelli Incalzi}, R. and A. Capone and F. Cortese and M. Sanguinetti and F. Spandonaro and A. Urbani and R. Murri",
year = "2019",
month = "1",
day = "1",
doi = "10.26355/eurrev_201904_17579",
language = "English",
volume = "23",
pages = "2978--2985",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "7",

}

TY - JOUR

T1 - The role of procalcitonin outside of the Intensive Care Unit (ICU)

T2 - A multidisciplinary approach

AU - Fantoni, M.

AU - Taddei, E.

AU - Cauda, R.

AU - Antonelli Incalzi, R.

AU - Capone, A.

AU - Cortese, F.

AU - Sanguinetti, M.

AU - Spandonaro, F.

AU - Urbani, A.

AU - Murri, R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - OBJECTIVE: Biochemical markers are commonly used in medicine to guide diagnostic investigation or therapy duration and/or monitor treatment efficacy. Due to the emergence and spread of antimicrobial resistance, markers able to prompt a more rational use of antimicrobial therapy are regarded with the greatest attention. Procalcitonin (PCT) certainly stands out among others, yet its role must be better established especially outside of the critical care area. Data about PCT utilization in non-critical patients, optimal negativity cut-offs as well as a protocol for measurement timing are all lacking. MATERIALS AND METHODS: To address these issues, a focus group was set up to propose and endorse shared statements regarding the most beneficial use of PCT in real life as infection marker for non-critical patients, based on the authors' experience and a review of recent literature. RESULTS: A group of nine experts in the fields of Infectious Diseases, Internal Medicine, Microbiology, Clinical Chemistry, Surgery and Medical Economics participated in the discussion of nine pre-specified statements. CONCLUSIONS: The potential role for PCT in differentiating infectious and non-infectious clinical syndromes and guiding antimicrobial therapy discontinuation was acknowledged. Moreover, a shared measurement protocol and desirable cut-offs for the non-critical area were proposed. Finally, observations were made about a reasonable selection of the patient population to be tested.

AB - OBJECTIVE: Biochemical markers are commonly used in medicine to guide diagnostic investigation or therapy duration and/or monitor treatment efficacy. Due to the emergence and spread of antimicrobial resistance, markers able to prompt a more rational use of antimicrobial therapy are regarded with the greatest attention. Procalcitonin (PCT) certainly stands out among others, yet its role must be better established especially outside of the critical care area. Data about PCT utilization in non-critical patients, optimal negativity cut-offs as well as a protocol for measurement timing are all lacking. MATERIALS AND METHODS: To address these issues, a focus group was set up to propose and endorse shared statements regarding the most beneficial use of PCT in real life as infection marker for non-critical patients, based on the authors' experience and a review of recent literature. RESULTS: A group of nine experts in the fields of Infectious Diseases, Internal Medicine, Microbiology, Clinical Chemistry, Surgery and Medical Economics participated in the discussion of nine pre-specified statements. CONCLUSIONS: The potential role for PCT in differentiating infectious and non-infectious clinical syndromes and guiding antimicrobial therapy discontinuation was acknowledged. Moreover, a shared measurement protocol and desirable cut-offs for the non-critical area were proposed. Finally, observations were made about a reasonable selection of the patient population to be tested.

KW - Antibiotic therapy

KW - Antimicrobial stewardship

KW - Biomarkers

KW - Procalcitonin

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=85064404568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064404568&partnerID=8YFLogxK

U2 - 10.26355/eurrev_201904_17579

DO - 10.26355/eurrev_201904_17579

M3 - Article

AN - SCOPUS:85064404568

VL - 23

SP - 2978

EP - 2985

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 7

ER -